 19 Sequential Increase in Total Revenue TigereyeTM Drives 38 Sequential Growth in Image-Guided CTO Revenue REDWOOD CITY, CA ACCESSWIRE March 11, 2021 Avinger, Inc. NASDAQ: AVGR, a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease PAD, today reported results for the fourth quarter ended December 31, 2020. Fourth Quarter and Recent Highlights Revenue increased 19 sequentially to 2.7 million, the highest level in 3 years Image-guided CTO revenue increased 38 sequentially, driven by limited launch of the new TigereyeTM device Gross margin rose sequentially to 36, reflecting increased sales activity and cost efficiency Opened 9 new Lumivascular accounts in the fourth quarter, bringing total new accounts for the full year to 36 Progressed Tigereye to full commercial launch in January 2021, following successful limited launch in the fourth quarter Improved the terms of Avingers existing loan agreement in January 2021, including the extension of the maturity date to 2025 Ended December 31, 2020 with cash on hand of 22.2 million and added approximately 13 million in net proceeds from a common stock offering in February 2021 Jeff Soinski, Avingers President and CEO, commented, Avinger remains focused on driving top-line growth by introducing new products, launching new accounts and expanding utilization at existing sites. 